Saturday, July 22, 2017 11:55:18 AM
The company has been realizing it's strategic vision and unfortunately having to make tough decisions to do so over the last two years. Now that they can just focus on sales and revs, An R/S is a bummer only because it reduces your share count. Its also a bummer if the company is in an already bad position, however this is no longer the case. If you have a company with growing revs and zero debt, an R/S would do little to devalue your share value. Book/Sales should grow and book/MRQ should grow if our ERs are good. Not that i'm for an R/S, I mean I think we all would love to have more shares worth more money
, however this is not the same company as even 6 months ago, Things have changed for the better and WS is starting to change their tune as well. All they need to do is show us good earnings and we are all set. If I were any other company, i'm keeping a VERY close eye on Amedica. If they need money down the road, being in a position with a better debt to income record will simply allow them to get a real loan or even other options, without impact to shareholders.
Recent SINT News
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
